Background. Although clinical guidelines exist for optimal levels of serum markers of chronic kidney disease mineral and bone disorder (CKD-MBD), target parameters are not achieved in many haemodialysis (HD) patients. The reason for this evidence-practice gap is unclear and more information from patients and healthcare professionals is required to improve knowledge transfer. We aimed to determine potential barriers by surveying HD patients and staff about awareness and management of CKD-MBD. Methods. A total of 136 prevalent HD patients, 25 nephrologists and 58 dialysis nurses/technicians were surveyed. Three separate questionnaires included issues of knowledge and awareness of CKD-MBD and factors limiting management (including compliance, medications and general understanding). Results. Of patients surveyed, 84% had heard of phosphate, but 42% were unsure of high phosphate foods and 46% unaware of consequences of elevated phosphate. Twenty-seven percent and thirty-five percent of patients, respectively, had difficulty taking or forgetting to take phosphate binders. Seventy-four percent of patients wanted to know more about CKD-MBD (40% via written material). Of nephrologists surveyed, 76% thought noncompliance with phosphate binders was the main reason for poor control of phosphate (predominantly related to poor patient understanding); 84% thought patients wanted to know more but only 28% provided written material on CKD-MBD. Of dialysis staff surveyed, 63% thought noncompliance with binders explained poor control, the main reason being lack of patient understanding; 88% thought patients wanted to know more but only 17% provided written education. Conclusions. Implementation of an intensive educational programme, with a multi-faceted approach, for HD patients may promote better control of CKD-MBD and improve achievement of target levels.
Introduction
Disorders of bone and mineral metabolism contribute to an increased prevalence of bone disease and cardiovascular disease in patients with chronic kidney disease (CKD). Hypercalcaemia, hyperphosphataemia and hyperparathyroidism are risk factors for vascular calcification and cardiovascular disease in patients with advanced CKD on dialysis, and elevated phosphate levels are independently associated with all-cause and cardiovascular mortality in this population [1] [2] [3] [4] . Recently the term 'Chronic Kidney Disease-Mineral and Bone Disorder' (CKD-MBD) has been applied to these disturbances of mineral metabolism, renal bone disease and vascular calcification, together with patient-level outcomes of fracture, cardiovascular disease and mortality in patients with CKD [5] .
Of the many complications of CKD, problems associated with derangements in CKD-MBD are probably the most complex and require a thorough understanding of the disease process for appropriate interventions to be introduced. Current management strategies for abnormalities of mineral metabolism in CKD predominantly involve the control of hyperphosphataemia and the use of vitamin D compounds and calcimimetic agents to suppress elevations in parathyroid hormone (PTH), with an aim to obtain normalization of serum calcium and phosphate. Phosphate control in CKD patients is difficult and management relies on dietary restriction (often not effective alone), the use of phosphate binders and dialysis therapy when end-stage kidney disease develops. Unfortunately despite current therapies, adequate control of serum markers of CKD-MBD, especially hyperphosphataemia, is poorly achieved [6] [7] [8] .
In medical practice, clinical guidelines have been developed as a means of improving quality of care and objective medical decision-making. However, many deficiencies in the application of guidelines have been described [9] . Multiple guidelines exist for the treatment of disorders of bone and mineral metabolism in CKD with target ranges for optimal levels of serum markers of calcium, phosphate and PTH [10] [11] [12] . More recently the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines group produced international recommendations for the diagnosis and management of CKD-MBD [13] . Despite the presumed benefits of maintaining calcium, phosphate and PTH concentrations within the proposed ranges of guidelines, evidence suggests that the vast majority of dialysis patients are uncontrolled in this regard. The reason for this evidence-practice gap is unclear and more information from patients and healthcare professionals is required to improve knowledge transfer.
Mineral metabolism control requires concurrent modulation of dietary intake, pharmacological therapy and dialysis prescription, with each of these being highly dependent on patient behaviour, the education and skill of healthcare providers and the quality of provider-patient communication. One way to ensure that CKD-MBD guidelines actually improve outcomes is to emphasize implementation strategies addressing these issues. We aimed to determine potential barriers for the current evidencepractice gap by surveying dialysis patients, nephrologists and dialysis staff about their awareness and management of CKD-MBD. This will identify reasons for deficiencies in implementation of guidelines and help guide interventions to improve the management of CKD-MBD.
Materials and methods
This study was a barrier analysis for a larger implementation project aiming to improve the management of CKD-MBD in dialysis patients. An initial survey was conducted to establish potential reasons for an evidence-practice gap in the treatment of bone and mineral disorders in dialysis patients with failure to meet target levels of serum markers in many patients. Patients, nephrologists and dialysis staff involved were those affiliated with the Departments of Nephrology at two tertiary referral institutions: Monash Medical Centre (MMC), Clayton and The Royal Melbourne Hospital (RMH), Parkville, Victoria, Australia. Three separate questionnaires were developed and distributed to haemodialysis (HD) patients, nephrologists and dialysis staff at satellite HD centres. Dialysis staff involved dialysis nurses and dialysis technicians as one of the institutions (RMH) primarily employed dialysis technicians to dialyse chronic HD patients in satellite units. Seven satellite dialysis centres (four associated with MMC and three with RMH) were involved with all patients and dialysis staff who were involved in this study attending for treatment or working at these centres. Participants were approached and asked to complete the questionnaires between January and April 2010. The survey was approved by local ethics committees at both institutions. Descriptive statistics were used to report the frequency for each response option from each survey question.
Questionnaires to nephrologists and dialysis staff included issues about knowledge and awareness of CKD-MBD, clinical management and perceived success and reasons for failure to achieve optimal treatment goals. The questionnaires to patients included issues addressing knowledge and awareness of CKD-MBD, potential factors limiting management including compliance and medication use and general understanding and interest to learn more. Patients eligible to participate were those aged 18 years or older, receiving chronic HD and cognitively able to complete the questionnaires in English (as perceived by their dialysis nurse or technician). Patients were permitted to complete the self-administered survey at the dialysis centre or at home, returning them when they next presented for treatment. The dialysis staff assisted with distribution and collection of questionnaires.
Results

Patient survey
Of 285 eligible HD patients that were approached, 136 patients (48%) completed the survey. Patient characteristics can be seen in Table 1 . Most patients were male (54%) and aged between 60 and 80 years (88%). Two thirds of patients were born in a country other than Australia and one quarter lived alone. Dialysis vintage was variable, with 35% of patients having been on HD for >5 years, and almost all patients (99%) were dialysing between 3 and 5 h, 3 days a week. Patients had a moderate tablet burden with 33% taking between 10 and 15 tablets daily and 28% taking more than 15 tablets daily. Most patients (68%) administered their own tablets independently from the medication packets or bottles.
Patients'self-reported knowledge is presented in Table 2 . Most patients (84%) had heard of phosphate, with infor- skin (46%), with fewer aware of bone problems (29%) and cardiac consequences (28%). From a list of foods, many patients were aware that cheese (39%), chocolate (35%) and nuts (30%) were high in phosphate; however, 43% of patients responded that they were unsure which foods were high in phosphate and 30% listed bananas as being phosphate-rich. The vast majority of patients surveyed (92%) were taking phosphate binders, although only 65% reported that they were aware of taking phosphate binders. Thirty-six percent of patients responded to being aware that they were taking vitamin D tablets (with 44 and 29% of patients actually treated with calcitriol and 25-hydroxy vitamin D, respectively). Thirty-two percent of patients admitted to taking tablets to 'help their bones'. Most patients (59%) also responded that they were taking calcium supplementation (65% surveyed were being administered calcium carbonate as a phosphate binder). Phosphate binders were generally administered with food with 63 and 21% of patients taking binders immediately after or immediately before they ate, respectively. Of patients who responded that they had difficultly taking phosphate binders (27%), 35% admitted to forgetting to take them but very few thought there were too many to take, couldn't afford them or didn't believe they were effective. Questions around the issue of improving patient education showed that most patients (75%) were interested in knowing more about bone and mineral problems in CKD, with 40% wanting to obtain written material as education and 21 and 24% wanting face-to-face education from doctors and nurses, respectively.
Nephrologist survey
Of 31 eligible nephrologists that were approached, 25 (81%) completed the survey. Nephrologist characteristics are shown in Table 3 . Nephrologists were predominantly male (60%) and had a variety of experience, with 60% practising as a nephrologist for >10 years. The majority (60%) were working in public practice. Table 4 shows the awareness and perceptions of CKD-MBD according Non-compliance with phosphate binders was thought by most nephrologists surveyed (76%) to be the most common reason for dialysis patients having persistent hyperphosphataemia. Few considered not enough dialysis or non-compliance with dietary phosphate restriction to be the most common reason. In patients who are noncompliant with phosphate binders, a lack of understanding about the importance and consequences of hyperphosphataemia was thought by 44% of nephrologists to be the predominant reason, with 36% listing that patients couldn't be bothered taking binders (because of no improvement in symptoms) and 28% listing lack of understanding about binders and how to take them as predominant reasons for patients being non-compliant. The vast majority of nephrologists (92%) thought dialysis patients would like to know more about CKD-MBD although only 28% provided written education material to patients on this subject.
Dialysis staff survey
Of 78 eligible dialysis nurses and technicians who were approached, 58 (74%) completed the survey. Characteristics of participating dialysis staff can be seen in Table 5 . The majority of dialysis staff (86%) were female with most (60%) under the age of 40 years. About half of those surveyed were dialysis nurses and the other half dialysis technicians. Table 6 lists the perceptions and awareness about CKD-MBD of the dialysis staff surveyed. The majority of dialysis staff (86%) had heard of CKD-MBD with 61% thinking that current management of this problem at their centre was satisfactory.
Most dialysis staff (63%) thought that patient noncompliance with phosphate binders was the most common reason for persistent hyperphosphataemia, with 29% responding that non-compliance with dietary phosphate restriction was the most common reason for this problem. In patients who are non-compliant, the predominant reason as listed by more than half of dialysis staff (55%) was a lack of understanding about the importance and consequences of hyperphosphataemia, with 38% reporting that patients forgetting to take phosphate binders contributed to this problem. The majority of dialysis staff (88%) thought patients wanted to know more about CKD-MBD, either by face-to-face education from doctors (60%) or nurses (31%) or written education material (31%). Only 17% provided written educational material about CKD-MBD to patients. Table 7 summarizes the percentages perceived by healthcare providers (nephrologists and dialysis staff) of achieving the target parameters for disorders of bone and mineral metabolism, according to local practice using the Caring for Australasians with Renal Impairment (CARI) guideline ranges for calcium, phosphate and PTH levels [10] . Comparison is made with the actual percentage of Australian HD patients achieving appropriate levels of calcium and phosphate from the latest Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry report [14] .
Discussion
Disturbances of bone and mineral metabolism are common in CKD and their long-term presence and associated complications are of growing concern in the care of dialysis patients. Several observational studies report a compelling association between abnormalities in serum phosphate, calcium, calcium-phosphate product and PTH and all-cause mortality and cardiovascular events [3, [15] [16] [17] [18] [19] . Unfortunately, regulation of mineral metabolic parameters remains an elusive goal for many individuals on dialysis despite clinical guidelines with evidence-based recommendations [6] [7] [8] 20] . We conducted a survey of dialysis patients and healthcare providers to determine potential barriers to the optimal management of CKD-MBD and report that a lack of patient understanding and awareness of this condition and its consequences may contribute to the evidence-practice gap.
Although the vast majority of dialysis patients surveyed in our study had heard of phosphate, most were unaware of the problems associated with hyperphosphataemia and many were unsure about food high in phosphate. Most patients completing the questionnaire were also unaware of problems with vitamin D and hyperparathyroidism, and many were unclear as to the reasons for taking various medications involved in the management of CKD-MBD. Three quarters of patients were interested in discovering more information about abnormalities of bone and mineral metabolism, predominantly requesting this in the form of written educational material. Interestingly, written material about CKD-MBD was only provided by 28% of nephrologists and 17% of dialysis staff in our nephrology units.
Despite formal pre-dialysis and dialysis education programmes for patients at our institutions as well as multidisciplinary standard clinical care involving information and education provided by nephrologists, dialysis staff, dieticians and pharmacists, our study revealed the potential to further enhance knowledge and awareness of CKD-MBD and subsequently improve management of this disorder. One way to ensure that clinical guidelines for the treatment of CKD-MBD actually improve outcomes is to emphasize implementation strategies [9] , and our survey highlighted scope for the nephrology team as a whole to focus on the importance of patient education of CKD-MBD to bridge the evidence-practice gap. Promoting and developing strategies to help patients understand the importance of adequate serum calcium, phosphate and PTH control are essential.
Implementation of an intensive educational programme, with a multi-faceted approach, would likely promote better control of CKD-MBD and improve achievement of target levels. Educational interventions, comprising different types of activities intended to increase the knowledge and skills of healthcare professionals and patients, have traditionally been the predominant approach to stimulate change and improvement in healthcare [21] . Multiple studies have demonstrated that active educational programmes are effective in changing health professional behaviour in managing patients, with small but clinically relevant improvements [22] . Optimizing the management of abnormalities of mineral metabolism in CKD through increased patient education has also previously been addressed with reports of numerous studies in HD patients showing benefits of educational interventions [23] [24] [25] [26] [27] [28] [29] . These studies have predominantly involved dietician-led education programmes, with increased dietary advice and improvement in patient knowledge of phosphate and phosphate binders, subsequently demonstrating significant reductions in serum phosphate levels. Educating and guiding patients towards overcoming the barriers for dealing with co-morbidities involved with CKD-MBD are a multidisciplinary project. In association, approaches to implementation of better practice could include the development of implementation support systems in dialysis centres, clinical audit programmes and methods of gathering and feeding back information regarding the process. A role for nurse practitioners specifically employed to educate and supervise CKD-MBD management may also be highly effective.
Although no prospective trials have assessed the effect of improving mineral metabolism control on hard patient outcomes, including death and cardiovascular events, [11] with only 40, 41 and 22% having serum phosphate, calcium and PTH levels, respectively, within the recommended ranges [7] . A recent Canadian study of 546 dialysis patients reported that between 53 and 81% of patients met targets recommended by KDOQI, but only 26% achieved all targets of calcium, phosphate and PTH [8] . Information from the latest ANZDATA report [14] also revealed that many Australian HD patients do not meet the recommended calcium and phosphate targets according to the CARI guidelines for management of bone and mineral disease in CKD [10] . Although guidelines on bone and mineral metabolism in CKD receive widespread attention, there is limited information on their impact in clinical practice. A Spanish study of 342 dialysis patients looked at changes in mineral metabolism after the KDOQI Guidelines for Bone Metabolism and Disease were introduced showing mild improvements in achievement of some targets, although no change in serum phosphate levels [30] . A study in the USA assessing the effect of these KDOQI Guidelines in the year after release reported only a small difference in a large cohort of dialysis patients [31] . On average, the proportion of calcium and phosphate readings within the prescribed targets in this study increased by 5 and 4%, respectively; however, serum phosphate levels exceeded 1.78 mmol/L on 40% of measurements.
Control of optimal serum phosphate levels in dialysis is poorly achieved. In addition to insufficient phosphate elimination with conventional HD, variability of dietary phosphate intake and inadequate phosphate binder dosing in relation to meal phosphate content contribute to hyperphosphataemia. The majority of nephrologists (80%) and dialysis nurses and technicians (91%) in our study responded that inadequate phosphate management was due to patient non-compliance with phosphate binders and dietary restrictions, with few in each group suggesting that inadequate dialysis was the major contributing factor. Most healthcare providers considered a lack of understanding and awareness of CKD-MBD was the major reason contributing to non-compliance reporting patient deficiencies in understanding of the consequences of hyperphosphataemia and the effects and importance of phosphate binders. Interestingly, 65% of patients knew that they take phosphate binders (84% indicated a time when they usually take their binder) and only 27% of patients had difficulty taking phosphate binders (35% admitted to having ever forgotten to take binders). Unfortunately, in our survey we did not include inadequate phosphate binder dosage as a reason for persistent hyperphosphataemia; however, these data suggest that inadequate phosphate binder dosing may be a potential reason for inability to achieve good phosphate control. Therefore, education may be necessary not only for patients but also for nephrologists and dialysis staff who may need to change their phosphate binder prescription patterns.
As each phosphate binder has a limited phosphatebinding capacity, dosing generally needs to be adapted to meal size and frequency or ideally to the estimated phosphate content of each meal. The self-adjustment of phosphate binder dose to meal phosphate content by patients has been a proposed strategy studied to improve management of hyperphosphataemia [23] , and one recent publication reported benefits of this intervention with an implementation study in children on dialysis [29] . Patient empowerment to improve clinical outcomes is not a new concept with this strategy having been tested in diseases such as diabetes and hypertension [32, 33] . Our study highlighted the extensive tablet burden of dialysis patients, especially those involved in the treatment of CKD-MBD. A formal education programme involving multiple healthcare providers, including clinical pharmacists, emphasizing the indications, importance and correct administration of tablets for dialysis patients would be helpful to bridge the evidence-practice gap. However, further studies supporting positive effects of patient empowerment on clinical outcomes in CKD-MBD patients are warranted. Regulation of CKD-MBD could also potentially be limited by the current therapies available, although newer medications helping to control hyperphosphataemia and hyperparathyroidism may help increase the achievement of target serum levels.
There are several limitations of this study, some of which are intrinsic to the use of questionnaires. Responses can be difficult to interpret because patients' and healthcare providers' understanding of questions and reasons why they answer as they do are not sought directly. Findings for the dialysis patients are limited to predominantly English-speaking patients, and there was only a 48% response rate for completion of questionnaires from the dialysis population approached. However, characteristics of patients in the study suggest that they are a representative sample of all satellite HD patients at our institutions and also have relatively similar patient demographics to those of the overall Australian HD population reported by AN-ZDATA [14] . The response rate from nephrologists and dialysis staff was excellent with 81 and 74% of those asked, respectively, completing the survey.
This study is a first step in identifying gaps between CKD-MBD evidence and guidelines in our dialysis population. We report the deficiencies in dialysis patient knowledge about CKD-MBD and the need for provision of more information to optimize care. Implementation of an intensive educational programme, with a multi-faceted approach, for patients may promote better control of CKD-MBD and improve achievement of target levels.
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